Global Enoxaparin Sodium Market Research Report 2022

Enoxaparin sodium is an anticoagulant medication (blood thinner).It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein.It is also used during hemodialysis.
Due to the COVID-19 pandemic, the global Enoxaparin Sodium market size is estimated to be worth US$ 3044.5 million in 2021 and is forecast to a readjusted size of US$ 5354.7 million by 2028 with a CAGR of 8.3% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Enoxaparin Sodium market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Enoxaparin Sodium landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Europe is the largest market of Enoxaparin Sodium, with about 60% market share, followed by North America with about 17% market share. Currently, there are many players in this market.Sanofi, Teva, Techdow (Hepalink), Fresenius Kabi, Rovi, Amphastar, Nanjing King-friend, Sandoz and some others are playing important roles in Enoxaparin sodium injection industry. Sanofi, Teva, Techdow (Hepalink), Fresenius Kabi and Rovi are the top 5 players of Enoxaparin Sodium, with about 85% market shares.
There are nine different dosage form of Enoxaparin Sodium. The market can be segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, 80 mg/0.8mL, 100 mg/1mL, 120 mg/0.8mL, 150 mg/1mL, 300mg/3mL. 40 mg/0.4mL is almost the only used and efficient types and took 40% market share. By application, Hospital is the largest consumer group, with market share of 63%.
This report focuses on Enoxaparin Sodium volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Enoxaparin Sodium market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Southeast Asia, South America, Japan, China and India, etc.
Global Enoxaparin Sodium Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
20 mg/0.2mL
30 mg/0.3mL
40 mg/0.4mL
60 mg/0.6mL
80 mg/0.8mL
100 mg/1mL
120 mg/0.8mL
150 mg/1mL
300mg/3mL
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Sanofi
Teva
Techdow (Hepalink)
Fresenius Kabi
Rovi
Amphastar
Nanjing King-friend
Sandoz
Apotex
Hangzhou Jiuyuan Gene Engineering
Cipla
Taj Pharma
Chengdu Baiyu Pharmaceutical
Suzhou Erye Pharmaceutical
Changzhou Qianhong Bio-pharma
Hebei Changshan Biochemical Pharmaceutical
Beijing SL Pharmaceutical
Huadong Medicine
Bharat Serums
INTAS
LUPIN
Troikaa Pharmaceuticals
Aristopharma
Fosun Pharma
SciencePharma
PISA